首页> 外文期刊>International Journal of Cardiology >Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score
【24h】

Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score

机译:N末端前B型利钠尿肽在急性失代偿性心力衰竭患者风险分层中的临床应用。 ADHF / NT-proBNP风险评分的推导和验证

获取原文
获取原文并翻译 | 示例
       

摘要

Background NT-proBNP has been associated with prognosis in acute decompensated heart failure (ADHF). Whether NT-proBNP provides additional prognostic information beyond that obtained from standard clinical variables is uncertain. We sought to assess whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) determination improves risk reclassification of patients with ADHF and to develop and validate a point-based NT-proBNP risk score. Methods This study included 824 patients with ADHF (453 in the derivation cohort, 371 in the validation cohort). We compared two multivariable models predicting 1-year all-cause mortality, including clinical variables and clinical variables plus NT-proBNP. We calculated the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI). Then, we developed and externally validated the NT-proBNP risk score. Results One-year mortalities for the derivation and validation cohorts were 28.3% and 23.4%, respectively. Multivariable predictors of mortality included chronic obstructive pulmonary disease, estimated glomerular filtration rate, sodium, hemoglobin, left ventricular ejection fraction, and moderate to severe tricuspid regurgitation. Adding NT-proBNP to the clinical variables only model significantly improved the NRI (0.129; p = 0.0027) and the IDI (0.037; p = 0.0005). In the derivation cohort, the NT-proBNP risk score had a C index of 0.839 (95% CI: 0.798-0.880) and the Hosmer-Lemeshow statistic was 1.23 (p = 0.542), indicating good calibration. In the validation cohort, the risk score had a C index of 0.768 (95% CI: 0.711-0.817); the Hosmer-Lemeshow statistic was 2.76 (p = 0.251), after recalibration. Conclusions The NT-proBNP risk score provides clinicians with a contemporary, accurate, easy-to-use, and validated predictive tool. Further validation in other datasets is advisable.
机译:背景NT-proBNP与急性失代偿性心力衰竭(ADHF)的预后相关。除从标准临床变量获得的信息外,NT-proBNP是否可提供其他预后信息尚不确定。我们试图评估N末端前B型利尿钠肽(NT-proBNP)的测定是否能改善ADHF患者的风险重分类,并开发和验证基于点的NT-proBNP风险评分。方法:本研究包括824例ADHF患者(派生队列453例,验证队列371例)。我们比较了两种预测1年全因死亡率的多变量模型,包括临床变量和临床变量以及NT-proBNP。我们计算了净重分类改进(NRI)和综合歧视改进(IDI)。然后,我们开发并从外部验证了NT-proBNP风险评分。结果派生和验证队列的一年死亡率分别为28.3%和23.4%。死亡率的多变量预测因素包括慢性阻塞性肺疾病,估计的肾小球滤过率,钠,血红蛋白,左心室射血分数和中度至重度三尖瓣关闭不全。仅将NT-proBNP添加到仅临床变量模型中可显着改善NRI(0.129; p = 0.0027)和IDI(0.037; p = 0.0005)。在派生队列中,NT-proBNP风险评分的C指数为0.839(95%CI:0.798-0.880),而Hosmer-Lemeshow统计值为1.23(p = 0.542),表明校正良好。在验证队列中,风险评分的C指数为0.768(95%CI:0.711-0.817);重新校准后,Hosmer-Lemeshow统计量为2.76(p = 0.251)。结论NT-proBNP风险评分为临床医生提供了一种现代,准确,易用且经过验证的预测工具。建议在其他数据集中进行进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号